V Dousset1, A Gayou, B Brochet, J M Caille. 1. Laboratoire de Neurobiologie et Neuro-imagerie Expérimentales, Université Victor-Segalen Bordeaux 2, France.
Abstract
BACKGROUND: Whether acute MS lesions are primarily inflammatory or demyelinative is unresolved. Our study examined acute MS lesions longitudinally by quantitative magnetization transfer (MT), an MRI technique that identifies tissue integrity and destruction. METHODS: Four MS patients were studied by serial MRI including MT, conventional T2-weighted images, and postgadolinium T1-weighted images for 9 to 12 months. In 15 new lesions, the MT ratio (MTR) was calculated retrospectively. RESULTS: In 13 lesions, a marked decrease in the MTR was present early during the first 2 months after the onset of the lesion and was followed by a variable increase. In two other lesions, the MTR progressively declined. CONCLUSIONS: These results suggest that major early structural changes compatible with demyelination and followed by remyelination and gliosis, or by continuous demyelination, occur in new MS lesions. The various MTR profiles provide in vivo confirmation of the current knowledge of the progression in MS lesions. Furthermore, MTR may be used to monitor in vivo drug efficacy in new MS lesions.
BACKGROUND: Whether acute MS lesions are primarily inflammatory or demyelinative is unresolved. Our study examined acute MS lesions longitudinally by quantitative magnetization transfer (MT), an MRI technique that identifies tissue integrity and destruction. METHODS: Four MS patients were studied by serial MRI including MT, conventional T2-weighted images, and postgadolinium T1-weighted images for 9 to 12 months. In 15 new lesions, the MT ratio (MTR) was calculated retrospectively. RESULTS: In 13 lesions, a marked decrease in the MTR was present early during the first 2 months after the onset of the lesion and was followed by a variable increase. In two other lesions, the MTR progressively declined. CONCLUSIONS: These results suggest that major early structural changes compatible with demyelination and followed by remyelination and gliosis, or by continuous demyelination, occur in new MS lesions. The various MTR profiles provide in vivo confirmation of the current knowledge of the progression in MS lesions. Furthermore, MTR may be used to monitor in vivo drug efficacy in new MS lesions.
Authors: Cornelia Laule; Irene M Vavasour; Shannon H Kolind; David K B Li; Tony L Traboulsee; G R Wayne Moore; Alex L MacKay Journal: Neurotherapeutics Date: 2007-07 Impact factor: 7.620
Authors: Vanessa Wiggermann; Enedino Hernández Torres; Irene M Vavasour; G R Wayne Moore; Cornelia Laule; Alex L MacKay; David K B Li; Anthony Traboulsee; Alexander Rauscher Journal: Neurology Date: 2013-06-12 Impact factor: 9.910
Authors: Wafaa Zaaraoui; Mathilde Deloire; Michel Merle; Céline Girard; Gérard Raffard; Marc Biran; Matilde Inglese; Klaus G Petry; Oded Gonen; Bruno Brochet; Jean-Michel Franconi; Vincent Dousset Journal: MAGMA Date: 2008-09-09 Impact factor: 2.310